Novel autophagy inducers by accelerating lysosomal clustering against Parkinson's disease

  1. Yuki Date
  2. Yukiko Sasazawa
  3. Mitsuhiro Kitagawa
  4. Kentaro Gejima
  5. Ayami Suzuki
  6. Hideyuki Saya
  7. yasuyuki kida
  8. Masaya Imoto
  9. Eisuke Itakura
  10. Nobutaka Hattori  Is a corresponding author
  11. Shinji Saiki  Is a corresponding author
  1. Chiba University, Japan
  2. Juntendo University, Japan
  3. Keio University, Japan
  4. National Institute of Advanced Industrial Science and Technology, Japan
  5. University of Tsukuba, Japan

Abstract

The autophagy-lysosome pathway plays an indispensable role in the protein quality control by degrading abnormal organelles and proteins including a-synuclein (aSyn) associated with the pathogenesis of Parkinson's disease (PD). However, the activation of this pathway is mainly by targeting lysosomal enzymic activity. Here, we focused on the autophagosome-lysosome fusion process around the microtubule-organizing center (MTOC) regulated by lysosomal positioning. Through high-throughput chemical screening, we identified 6 out of 1,200 clinically approved drugs enabling the lysosomes to accumulate around the MTOC with autophagy flux enhancement. We further demonstrated that these compounds induce the lysosomal clustering through a JIP4-TRPML1-dependent mechanism. Among them, the lysosomal-clustering compound albendazole promoted the autophagy-dependent degradation of Triton-X-insoluble, proteasome inhibitor-induced aggregates. In a cellular PD model, albendazole boosted insoluble aSyn degradation. Our results revealed that lysosomal clustering can facilitate the breakdown of protein aggregates, suggesting that lysosome-clustering compounds may offer a promising therapeutic strategy against neurodegenerative diseases characterized by the presence of aggregate-prone proteins.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files

Article and author information

Author details

  1. Yuki Date

    Department of Biology, Chiba University, Chiba, Japan
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0009-0004-1099-1829
  2. Yukiko Sasazawa

    Department of Neurology, Juntendo University, Tokyo, Japan
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0287-273X
  3. Mitsuhiro Kitagawa

    Department of Neurology, Juntendo University, Tokyo, Japan
    Competing interests
    The authors declare that no competing interests exist.
  4. Kentaro Gejima

    Department of Neurology, Juntendo University, Tokyo, Japan
    Competing interests
    The authors declare that no competing interests exist.
  5. Ayami Suzuki

    Department of Neurology, Juntendo University, Tokyo, Japan
    Competing interests
    The authors declare that no competing interests exist.
  6. Hideyuki Saya

    Division of Gene Regulation, Keio University, Tokyo, Japan
    Competing interests
    The authors declare that no competing interests exist.
  7. yasuyuki kida

    Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Ibaraki, Japan
    Competing interests
    The authors declare that no competing interests exist.
  8. Masaya Imoto

    Division for Development of Autophagy Modulating Drugs, Juntendo University, Tokyo, Japan
    Competing interests
    The authors declare that no competing interests exist.
  9. Eisuke Itakura

    Department of Biology, Chiba University, Chiba, Japan
    Competing interests
    The authors declare that no competing interests exist.
  10. Nobutaka Hattori

    Department of Neurology, Juntendo University, Tokyo, Japan
    For correspondence
    nhattori@juntendo.ac.jp
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2305-301X
  11. Shinji Saiki

    Department of Neurology, University of Tsukuba, Tsukuba, Japan
    For correspondence
    ssaiki@md.tsukuba.ac.jp
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9732-8488

Funding

Japan Society for the Promotion of Science London (18K15464 21K07425)

  • Yukiko Sasazawa

Japan Society for the Promotion of Science London (18KK0242 18KT0027 22H02986)

  • Shinji Saiki

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2024, Date et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yuki Date
  2. Yukiko Sasazawa
  3. Mitsuhiro Kitagawa
  4. Kentaro Gejima
  5. Ayami Suzuki
  6. Hideyuki Saya
  7. yasuyuki kida
  8. Masaya Imoto
  9. Eisuke Itakura
  10. Nobutaka Hattori
  11. Shinji Saiki
(2024)
Novel autophagy inducers by accelerating lysosomal clustering against Parkinson's disease
eLife 13:e98649.
https://doi.org/10.7554/eLife.98649

Share this article

https://doi.org/10.7554/eLife.98649

Further reading

    1. Cell Biology
    Chengfang Pan, Ying Liu ... Changlong Hu
    Research Article

    Prostaglandin E2 (PGE2) is an endogenous inhibitor of glucose-stimulated insulin secretion (GSIS) and plays an important role in pancreatic β-cell dysfunction in type 2 diabetes mellitus (T2DM). This study aimed to explore the underlying mechanism by which PGE2 inhibits GSIS. Our results showed that PGE2 inhibited Kv2.2 channels via increasing PKA activity in HEK293T cells overexpressed with Kv2.2 channels. Point mutation analysis demonstrated that S448 residue was responsible for the PKA-dependent modulation of Kv2.2. Furthermore, the inhibitory effect of PGE2 on Kv2.2 was blocked by EP2/4 receptor antagonists, while mimicked by EP2/4 receptor agonists. The immune fluorescence results showed that EP1–4 receptors are expressed in both mouse and human β-cells. In INS-1(832/13) β-cells, PGE2 inhibited voltage-gated potassium currents and electrical activity through EP2/4 receptors and Kv2.2 channels. Knockdown of Kcnb2 reduced the action potential firing frequency and alleviated the inhibition of PGE2 on GSIS in INS-1(832/13) β-cells. PGE2 impaired glucose tolerance in wild-type mice but did not alter glucose tolerance in Kcnb2 knockout mice. Knockout of Kcnb2 reduced electrical activity, GSIS and abrogated the inhibition of PGE2 on GSIS in mouse islets. In conclusion, we have demonstrated that PGE2 inhibits GSIS in pancreatic β-cells through the EP2/4-Kv2.2 signaling pathway. The findings highlight the significant role of Kv2.2 channels in the regulation of β-cell repetitive firing and insulin secretion, and contribute to the understanding of the molecular basis of β-cell dysfunction in diabetes.

    1. Cell Biology
    Weihua Wang, Junqiao Xing ... Zhangfeng Hu
    Research Article

    Existence of cilia in the last eukaryotic common ancestor raises a fundamental question in biology: how the transcriptional regulation of ciliogenesis has evolved? One conceptual answer to this question is by an ancient transcription factor regulating ciliary gene expression in both uni- and multicellular organisms, but examples of such transcription factors in eukaryotes are lacking. Previously, we showed that an ancient transcription factor X chromosome-associated protein 5 (Xap5) is required for flagellar assembly in Chlamydomonas. Here, we show that Xap5 and Xap5-like (Xap5l) are two conserved pairs of antagonistic transcription regulators that control ciliary transcriptional programs during spermatogenesis. Male mice lacking either Xap5 or Xap5l display infertility, as a result of meiotic prophase arrest and sperm flagella malformation, respectively. Mechanistically, Xap5 positively regulates the ciliary gene expression by activating the key regulators including Foxj1 and Rfx families during the early stage of spermatogenesis. In contrast, Xap5l negatively regulates the expression of ciliary genes via repressing these ciliary transcription factors during the spermiogenesis stage. Our results provide new insights into the mechanisms by which temporal and spatial transcription regulators are coordinated to control ciliary transcriptional programs during spermatogenesis.